August 24, 2026 ImmunoForge Selected for the Ministry of SMEs and Startups’ ‘Global TIPS R&D’ Program… “Expansion of the LMT Platform”
August 24, 2026 European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union